Search Results - "Raventós, Aida"

Non‐additive effect on thrombin generation when a plasma‐derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro by Bravo, María Isabel, Raventós, Aida, Pérez, Alba, Costa, Montserrat, Willis, Todd

“…Background Emicizumab is an alternative non‐factor approach for treating patients with hemophilia A. However, there is a potential risk of thrombotic events…”
Get full text

Combination of emicizumab and factor VIII has no additive effects after reaching normal coagulation levels: Response to J Puetz (Are there additive effects between emicizumab and factor VIII?) by Maria‐Isabel Bravo, Raventós, Aida, Pérez, Alba, Costa, Montserrat, Willis, Todd

Get full text

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study by Bravo, Maria Isabel, Pérez, Alba, Raventós, Aida, Grancha, Salvador, Jorquera, Juan Ignacio, Butta, Nora Viviana, Álvarez‐Román, Maria Teresa, Costa, Montserrat, Willis, Todd, Jiménez‐Yuste, Victor

“…Introduction Presence of von Willebrand factor (VWF) in FVIII concentrates offers protection against neutralizing inhibitors in haemophilia A (HA). Whether…”
Get full text

Short-fiber protein of ad40 confers enteric tropism and protection against acidic gastrointestinal conditions by Rodríguez, Ester, Romero, Carolina, Río, Adolfo, Miralles, Marta, Raventós, Aida, Planells, Laura, Burgueño, Joan F, Hamada, Hirofumi, Perales, Jose Carlos, Bosch, Assumpció, Gassull, Miguel Angel, Fernández, Ester, Chillon, Miguel

“…The lack of vectors for selective gene delivery to the intestine has hampered the development of gene therapy strategies for intestinal diseases. We…”
Get more information

Combination of emicizumab and factor VIII has no additive effects after reaching normal coagulation levels by Bravo, Maria‐Isabel, Raventós, Aida, Pérez, Alba, Costa, Montserrat, Willis, Todd

Get full text

Ex Vivo Evaluation of the Effect of Plasma-Derived Factor VIII/Von Willebrand Factor in Patients with Severe Hemophilia_A on Prophylaxis with Emicizumab By Thrombin Generation Assay by Bravo, Maria-Isabel, Raventós, Aida, Pérez, Alba, G Arias-Salgado, Elena, Alvarez Román, María Teresa, Butta, Nora V., Jiménez-Yuste, Víctor, Costa, Montserrat, Willis, Todd

“…Introduction: Hemophilia A (HA) patients under emicizumab prophylaxis treatment may require the concomitant use of procoagulant factors for breakthrough…”
Get full text

Long-term 20% albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis by Horrillo, Raquel, Mestre, Anna, Ortiz, Ana Maria, Pérez, Alba, Raventós, Aida, Torres, Mireia, Páez, Antonio, Arroyo, Vicente, Fernandez, Javier, Clària, Joan, Willis, Todd, Costa, Montserrat

Get full text

SAT207 - Long-term 20% albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis by Horrillo, Raquel, Mestre, Anna, Ortiz, Ana Maria, Pérez, Alba, Raventós, Aida, Torres, Mireia, Páez, Antonio, Arroyo, Vicente, Fernandez, Javier, Clària, Joan, Willis, Todd, Costa, Montserrat

Get full text